What is the main business of Scimmune?

The main business activity of Scimmune focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on May 18, 2023.

Where is the headquarters located?

The headquarters is located at: ul. Mazowiecka 3, 92-215 Łódź.

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What was the revenue?

In 2025, the company generated total revenue of $24.

No, the company recorded a net loss of $61 in 2025. For comparison, in 2024 the loss was $867, meaning the company reduced its loss by 93.0%.

What is the main operating cost?

The largest operating cost category falls under other operating costs. This category amounted to $85 in 2025, representing 100% of all operating expenses.

Scimmunesp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Suspended

Registry date

2023-05-18

Share capital

5,000.00 PLN

Registered address

ul. Mazowiecka 3, 92-215 Łódź, Poland

Financials

Revenue history

Filing timeliness

Financial statements were filed on time, on average 50 days early.

202522/05/2026
202411/06/2025
202313/05/2024

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Industry · Research and experimental development on biotechnology352 / 386

Top 91%

Division · Scientific research and development1,826 / 1,953

Top 94%

Sector · Professional, scientific and technical activities37,729 / 39,211

Top 96%

City · Łódź7,752 / 8,065

Top 96%

Voivodeship · Łódzkie14,817 / 15,303

Top 97%

Country · Poland287,619 / 297,932

Top 97%

Results vs industry

Revenue

This companyUSD 23.86MedianUSD 55.66kAverageUSD 2.70m

Net profit

This companyUSD -60.93MedianUSD -1.27kAverageUSD -92.16k

Operating costs

This companyUSD 84.78MedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 79.14MedianUSD 133.19kAverageUSD 3.03m

Industry

Authorized Representatives

Przemysław Andrzej Lewkowiczage 57 – President of the Management Board

Magdalena Anna Namiecińskaage 48 – Management Board Member

Paweł Waldemar Piątekage 35 – Vice President of the Management Board

Manner of representation

In the case of a management board consisting of at least two members, submitting declarations of will requires joint action by two members of the management board or by one member of the management board jointly with a commercial proxy.

Ownership

Owner	Shares	Share value	Stake
Przemysław Andrzej Lewkowiczage 57	33	$445.71	33%
Magdalena Anna Namiecińskaage 48	30	$405.19	30%
Paweł Waldemar Piątekage 35	32	$432.20	32%
Others	5	$67.53	5%

Beneficial owners

Person	Rights

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Proteon PharmaceuticalsS.A.	$2,026,826.52	proteonpharmaspolkaakcyjna.pl
Centrum Badań Weterynaryjnych Vetcomplexsp. z o.o.	$255,522.81	vetcomplex.pl
UveraS.A.	$155,384.29	uvera.eu
Luna Laboratorysp. z o.o.	$61,894.23	lunalab.pl
Centrum Transferu Technologii Meditransfer Iitdsp. z o.o.	$228.56	iitd.pan.wroc.pl
Fungotechsp. z o.o.	$187.68	fungo.tech
Wavex Energysp. z o.o.	$142.33	wavexenergy.com
Ncage TherapeuticsS.A.	$29.14	ncage.org
Innervisionsp. z o.o.	$4.54	innervision.pl
ImmunotronicsP.S.A.	$0.16	immunotronics.net